These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

723 related items for PubMed ID: 24402162

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia.
    Elala YC, Lasho TL, Gangat N, Finke C, Barraco D, Haider M, Abou Hussein AK, Hanson CA, Ketterling RP, Pardanani A, Tefferi A.
    Am J Hematol; 2016 May; 91(5):503-6. PubMed ID: 26890983
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Somatic mutations of calreticulin in myeloproliferative neoplasms.
    Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, Ferretti V, Elena C, Schischlik F, Cleary C, Six M, Schalling M, Schönegger A, Bock C, Malcovati L, Pascutto C, Superti-Furga G, Cazzola M, Kralovics R.
    N Engl J Med; 2013 Dec 19; 369(25):2379-90. PubMed ID: 24325356
    [Abstract] [Full Text] [Related]

  • 9. Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.
    Al Assaf C, Van Obbergh F, Billiet J, Lierman E, Devos T, Graux C, Hervent AS, Emmerechts J, Tousseyn T, De Paepe P, Papadopoulos P, Michaux L, Vandenberghe P.
    Haematologica; 2015 Jul 19; 100(7):893-7. PubMed ID: 25934766
    [Abstract] [Full Text] [Related]

  • 10. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.
    Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, Gangat N, Fjerza R, Belachew AA, Lasho TL, Ketterling RP, Hanson CA, Rambaldi A, Finazzi G, Thiele J, Barbui T, Pardanani A, Vannucchi AM.
    Blood; 2014 Oct 16; 124(16):2507-13; quiz 2615. PubMed ID: 25037629
    [Abstract] [Full Text] [Related]

  • 11. Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis.
    Palandri F, Latagliata R, Polverelli N, Tieghi A, Crugnola M, Martino B, Perricone M, Breccia M, Ottaviani E, Testoni N, Merli F, Aversa F, Alimena G, Cavo M, Martinelli G, Catani L, Baccarani M, Vianelli N.
    Leukemia; 2015 Jun 16; 29(6):1344-9. PubMed ID: 25801912
    [Abstract] [Full Text] [Related]

  • 12. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.
    Tefferi A, Barbui T.
    Am J Hematol; 2017 Jan 16; 92(1):94-108. PubMed ID: 27991718
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Frequencies, clinical characteristics, and outcome of somatic CALR mutations in JAK2-unmutated essential thrombocythemia.
    Chen CC, Gau JP, Chou HJ, You JY, Huang CE, Chen YY, Lung J, Chou YS, Leu YW, Lu CH, Lee KD, Tsai YH.
    Ann Hematol; 2014 Dec 16; 93(12):2029-36. PubMed ID: 25015052
    [Abstract] [Full Text] [Related]

  • 16. The germline JAK2 GGCC (46/1) haplotype and survival among 414 molecularly-annotated patients with primary myelofibrosis.
    Tefferi A, Lasho TL, Mudireddy M, Finke CM, Hanson CA, Ketterling RP, Gangat N, Pardanani A.
    Am J Hematol; 2019 Mar 16; 94(3):299-305. PubMed ID: 30516848
    [Abstract] [Full Text] [Related]

  • 17. The clinical and prognostic relevance of driver mutations in 203 Taiwanese patients with primary myelofibrosis.
    Kuo MC, Lin TH, Sun CF, Lin TL, Wu JH, Wang PN, Huang YJ, Chang H, Huang TY, Shih LY.
    J Clin Pathol; 2018 Jun 16; 71(6):514-521. PubMed ID: 29203554
    [Abstract] [Full Text] [Related]

  • 18. MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT.
    Poluben LO, Neumerzhytska LV, Klymenko SV, Fraenkel P, Balk C, Shumeiko OO.
    Probl Radiac Med Radiobiol; 2020 Dec 16; 25():362-373. PubMed ID: 33361847
    [Abstract] [Full Text] [Related]

  • 19. Calreticulin mutation profile in Indian patients with primary myelofibrosis.
    Sazawal S, Singh N, Mahapatra M, Saxena R.
    Hematology; 2015 Dec 16; 20(10):567-70. PubMed ID: 25959795
    [Abstract] [Full Text] [Related]

  • 20. Effect of CALR and JAK2 mutations on the clinical and hematological phenotypes of the disease in patients with myelofibrosis - long-term experience from a single center.
    Palova M, Szotkowski T, Hlusi A, Indrak K, Navratilova J, Divoka M, Papajik T.
    Neoplasma; 2018 Dec 16; 65(2):296-303. PubMed ID: 29534592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.